InfuSystem Holdings (INFU) Receives Buy Rating – Analyst See’s Margin Expansion

InfuSystem Holdings (NYSEAMERICAN: INFU) has received a new “Buy” rating from Roth Capital, coupled with a compelling narrative of operational efficiency and scalability, that is turning heads on Wall Street.

Analyst Kyle Bauser’s initiation of coverage with a $12 price target, more than double the current price, suggests a significant upside potential that has the stock moving up today. INFU is trading 3.8% up, whilst the S&P 500 trades down 0.1$ on the day.

Roth Capital’s bullish stance is rooted in InfuSystem’s unique business model. The company operates through two key segments: Patient Services and Device Solutions.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

The magic, according to Bauser, lies in InfuSystem’s ability to automate critical processes such as billing, patient record management, and pump tracking. This automation allows the company to efficiently serve a growing customer base without the need for a linear increase in headcount, a key driver of margin expansion.

This perspective resonates with the broader analyst community, with a consensus 12-month price target of $13.00, even higher than Roth Capital’s target.

This consensus suggests a strong belief in InfuSystem’s underlying value and its potential to rebound.

Recent financial results further support the bullish case. In the first quarter of 2025, InfuSystem reported a 9% increase in net revenues, reaching $34.7 million.

The Patient Services segment led the charge with a 12% revenue increase, while the Device Solutions segment grew by 4%.

More impressively, adjusted EBITDA soared by 64% year-over-year to $6.3 million, with the adjusted EBITDA margin expanding by 6.2% to 18.2%.